Related Experiment Video
Updated: Sep 15, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Targeting TIM-3 to halt lung precancer progression
Kostas A Papavassiliou1, Alice G Vassiliou2, Athanasios G Papavassiliou3
1First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Abstract:
Little is known about lung precancer progression. Recently, Zhu et al. explored the early immunologic landscape of lung adenocarcinoma (LUAD) precursors and identified T cell immunoglobulin and mucin domain 3 (TIM-3) as a putative immune checkpoint target for precancer interception. TIM-3 blockade in mice harboring premalignant lesions delayed progression to invasive adenocarcinoma, suggesting potential clinical utility in high-risk individuals detected through screening.
Insights
Researchers studied lung adenocarcinoma precursors and found T cell immunoglobulin and mucin domain 3 (TIM-3) may be a target. Blocking TIM-3 in mice delayed precancer progression, showing potential for high-risk individuals.
Area of Science:
- Oncology
- Immunology
- Preclinical Research
Background:
- Lung adenocarcinoma (LUAD) precancer progression remains poorly understood.
- Early immune responses in LUAD precursors are critical for understanding disease development.
Purpose of the Study:
- To investigate the early immunologic landscape of lung adenocarcinoma (LUAD) precursors.
- To identify potential immune checkpoint targets for precancer interception in LUAD.
Main Methods:
- Exploration of the immunologic microenvironment in LUAD precursors.
- In vivo studies involving TIM-3 blockade in mice with premalignant lung lesions.
Main Results:
- T cell immunoglobulin and mucin domain 3 (TIM-3) was identified as a potential immune checkpoint target.
- TIM-3 blockade significantly delayed the progression from premalignant lesions to invasive adenocarcinoma in a mouse model.
Conclusions:
- TIM-3 represents a promising therapeutic target for intercepting LUAD precancer.
- Targeting TIM-3 may offer clinical utility for individuals at high risk for lung adenocarcinoma.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
